The Curcumin Derivative, H10, Suppresses Hormone-Dependent Prostate Cancer by Inhibiting 17β-Hydroxysteroid Dehydrogenase Type 3

Yating Cheng, Yan Yang, Yinan Wu, Wencheng Wang, Lichun Xiao, Yifan Zhang, Jianzhong Tang, Yadong Huang, Shu Zhang, Qi XiangFrontiers in Pharmacology 2020 · DOI

Abstract

The 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) enzyme is a potential therapeutic target for hormone-dependent prostate cancer, as it is the key enzyme in the last step of testosterone (T) biosynthesis. A curcumin analog, H10, was optimized for inhibiting T production in LC540 cells that stably overexpressed 17β-HSD3 enzyme (LC540 (17β-HSD3)) (P0.05). This indicated that H10 only inhibited the enzymatic activity of 17β-HSD3 in vitro. Furthermore, H10 inhibited the adione-stimulated growth of xenografts established from LNCaP cells in nude mice in vivo. We conclude that H10 could serve as an effective inhibitor of 17β-HSD3, which in turn would inhibit the biosynthesis of androgens and progression of prostate cancer.

Introduction: The Challenge of Androgen Deprivation

Prostate cancer remains a leading cause of cancer-related mortality in men, primarily due to its reliance on androgens like testosterone (T) and dihydrotestosterone (DHT) for growth. The current standard of care, androgen deprivation therapy (ADT), aims to lower systemic androgen levels through chemical or surgical castration. While effective initially, ADT often leads to treatment resistance and significant side effects, including cardiovascular disease and osteoporosis, because it disrupts hormonal balance throughout the body.

To address these limitations, researchers are investigating more targeted approaches. One promising strategy is the inhibition of 17β-Hydroxysteroid Dehydrogenase Type 3 (17β-HSD3). This enzyme catalyzes the final, crucial step in testosterone biosynthesis: the conversion of androstenedione (Adione) into testosterone.

Schematic depicting the synthesis of testosterone (T) and the role of 17β-HSD3 in the steroidogenic pathway.

Developing a Targeted Inhibitor: The H10 Analog

Curcumin, a natural compound found in turmeric, has long been studied for its anti-cancer properties, but its low bioavailability and lack of potency have hindered clinical use. In this study, researchers synthesized 12 mono-carbonyl analogs of curcumin to identify a more effective inhibitor of 17β-HSD3.

Through screening in LC540 cells engineered to overexpress the target enzyme, the analog H10—distinguished by chloride substituents on its aromatic rings—emerged as the most potent candidate. Experimental results demonstrated that H10 significantly reduced testosterone production compared to other analogs and the control group.

Inhibition of testosterone (T) production by curcumin analogs H1-H12, identifying H10 as a highly effective inhibitor.

Mechanism and Specificity

A key finding of the research was that H10 inhibits the enzymatic activity of 17β-HSD3 rather than its expression. Levels of mRNA and protein for the enzyme remained unchanged, suggesting H10 interacts directly with the enzyme's active or allosteric sites.

Furthermore, H10 exhibited remarkable specificity. While it drastically reduced testosterone levels, it did not significantly affect the production of progesterone, another vital steroid hormone. This selectivity is critical for a therapeutic agent, as it suggests H10 can suppress prostate cancer growth without broadly interfering with other essential endocrine pathways.

In Vivo Efficacy and Safety

The study extended these findings to animal models. In nude mice bearing LNCaP human prostate cancer xenografts, treatment with H10 (50 mg/kg) resulted in a dramatic reduction in tumor volume—approximately 271 mm³ compared to over 800 mm³ in control groups. Histological analysis revealed significant tissue necrosis within the tumors of H10-treated mice.

Importantly, H10 appeared well-tolerated. In Sprague-Dawley rats, while serum testosterone levels were lowered in a dose-dependent manner, there were no significant changes in the weights of reproductive organs, indicating a more favorable safety profile than traditional castration methods.

Conclusion

The curcumin derivative H10 represents a promising new lead in the fight against hormone-dependent prostate cancer. By specifically targeting the final step of testosterone synthesis via 17β-HSD3 inhibition, H10 offers a potential path toward effective tumor suppression with reduced systemic toxicity. Future research will focus on validating these results in human enzyme models and elucidating the precise molecular binding mechanism to pave the way for clinical trials.

Summary updated

Abstract

The 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) enzyme is a potential therapeutic target for hormone-dependent prostate cancer, as it is the key enzyme in the last step of testosterone (T) biosynthesis. A curcumin analog, H10, was optimized for inhibiting T production in LC540 cells that stably overexpressed 17β-HSD3 enzyme (LC540 (17β-HSD3)) (P0.05). This indicated that H10 only inhibited the enzymatic activity of 17β-HSD3 in vitro. Furthermore, H10 inhibited the adione-stimulated growth of xenografts established from LNCaP cells in nude mice in vivo. We conclude that H10 could serve as an effective inhibitor of 17β-HSD3, which in turn would inhibit the biosynthesis of androgens and progression of prostate cancer.
BibTeX
@inproceedings{cheng2020curcumin,
  author = {Yating Cheng and Yan Yang and Yinan Wu and Wencheng Wang and Lichun Xiao and Yifan Zhang and Jianzhong Tang and Yadong Huang and Shu Zhang and Qi Xiang},
  title = {{The Curcumin Derivative, H10, Suppresses Hormone-Dependent Prostate Cancer by Inhibiting 17β-Hydroxysteroid Dehydrogenase Type 3}},
  booktitle = {Frontiers in Pharmacology},
  year = {2020},
  doi = {10.3389/fphar.2020.00637},
}
Figure